Search Results - drew+pardoll

15 Results

Sort By:

Novel Targets for Combination Neoadjuvant Immunotherapy in Resectable Lung Cancer

Unmet NeedLung cancer is the leading cause of cancer related deaths [1,2]. It is estimated to result in approximately 131880 deaths in the US annually and causes more deaths in men and women than prostate and breast cancer, respectively [2]. Immune checkpoint inhibitors have become a useful therapeutic for certain cancers. However, the therapeutic effect...

Published: 9/27/2024 | Inventor(s): Kellie Smith, Drew Pardoll, Justina Caushi, Jiajia Zhang

Keywords(s):

Category(s):

B7-DC Knockout Mice

Detailed DescriptionThe Pdcd1lg2 gene encodes the costimulatory molecule PD-L2 which is expressed in dendritic cells (DCs). To establish the mouse line Stk 017515 - B6N.129(Cg)-Pdcd1lg2tm2Dmp/J which is deficient for PD-L2, a genomic fragment containing exon 2 of the programmed cell death 1 ligand 2 (Pdcd1lg2 which encodes PD-L2) gene, two of loxP sites...

Published: 9/26/2024 | Inventor(s): Drew Pardoll, Lieping Chen, Kevin Gorski, Haruo Tsuchiya, Tahiro Shin

Keywords(s): Discovery/Research Tools, In Vivo Research Tool, Knock Out Mouse Model, Mouse Model, Translational Research Biomarker

Category(s): Technology Classifications > Research Tools > Animal Models

Microsatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition

TITLEMicrosatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition CASE NUMBER C13241UNMET NEEDThe programmed death 1 (PD-1) pathway is a negative feedback system that represses Th1 cytotoxic immune responses and that, if unregulated, can damage the host. It is up-regulated in many tumors...

Published: 9/26/2024 | Inventor(s): Luis Diaz, Bert Vogelstein, Kenneth Kinzler, Nickolas Papadopoulos, Dung Le, Drew Pardoll, Suzanne Topalian

Keywords(s): Biomarker, Clinical Diagnostics, In Vitro Diagnostics, Pharmakodynamic Biomarker

Category(s): Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics

Targeting Interleukin 17 and Senescent Cells for Treatment of the Foreign Body Response

Unmet Need13 million medical devices are implanted annually in the United States. Synthetic biomaterials are the building blocks of these implanted devices. Although biomaterials are selected for durability and minimal host immune response, all implanted biomaterials induce the foreign body response (FBR) to some degree, which creates a capsule of fibrous...

Published: 9/27/2024 | Inventor(s): Jennifer Elisseeff, Drew Pardoll, Franck Housseau, Liam Chung

Keywords(s): Antagonists/Inhibitors, Implants, Small Molecules, Target, Therapeutic Devices, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Traumatic Injury, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Medical Devices > Prosthetics

Neuritin Impact T Cell Tolerance Induction and Maintenance and is a Target for Tumor Immunotherapy

Unmet NeedCancer immunotherapy is a therapeutic approach that has revolutionized advanced cancer treatment. In particular, the use of therapeutic blocking antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein (PD-1) has achieved routine clinical use in numerous indications. Despite these promising results, monotherapy...

Published: 9/27/2024 | Inventor(s): Drew Pardoll, Hong Yu, Joseph Barbi, Fan Pan, Charles Drake

Keywords(s): Antibodies, Autoimmune Diseases, Biologics, Cancers, Combination, Disease Indication, Inflammatory Disorders, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Detection and Elimination of Colonic Co-colonization with Enterotoxigenic Bacteroides Fragilis and pks+ Escherichia Coli in the Prevention of Colon Cancer

Unmet NeedFamilial adenomatous polyposis (FAP) is a hereditary condition caused by a mutation in the APC tumor suppressor gene, with a reported incidence of 1 in 7,000 to 1 in 22,000 individuals. Patients with FAP develop thousands of colorectal polyps that will eventually become malignant, resulting in colorectal cancer later in life. The onset and...

Published: 9/26/2024 | Inventor(s): Cynthia Sears, Christine Craig, Drew Pardoll

Keywords(s): Assay, Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Discovery/Research Tools, Disease Indication, Gastric Cancer, In Vitro Diagnostics (Old), In Vitro Research Tool, Research Instrument

Category(s): Clinical and Disease Specializations > Oncology > Colorectal Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays

Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists

Unmet NeedThe recent breakthroughs in immuno-oncology have changed the way that researchers think about treating autoimmune diseases and cancer by modulating the immune system. Regulatory T cells (Treg) limit autoimmunity but also attenuate the potency of antitumor immunity. Enhancement of Treg function could treat autoimmune diseases while the inhibition...

Published: 9/26/2024 | Inventor(s): Drew Pardoll, Joseph Barbi, Fan Pan, Hong Yu, Ching-Tai Huang, Xiaoyu Pan, Charles Drake, Jonathan Powell

Keywords(s): Antibodies, Biologics, Cancers, Disease Indication, Immunotherapy, Infectious Diseases, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics

Biofilm Formation to Define Risk for Colon Cancer

Biofilm Detection to Define Risk for Colon CancerJHU REF: C12695Invention novelty: This technology is a diagnostic method for identifying people at risk for colon cancer employing analysis of biopsy specimens for biofilm formation. Value Proposition:Colorectal cancer is the third most commonly diagnosed cancer in the world. According to the American...

Published: 9/26/2024 | Inventor(s): Drew Pardoll, Elizabeth Wick, Christine Craig, Cynthia Sears

Keywords(s): Assay, Cancers, Clinical Diagnostics, Colorectal Cancer, Disease Indication, In Vitro Diagnostics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Colorectal Cancer, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools

Targeting YAP Activity in Combination with Immunomodulation to Alter Regulatory T Cell-mediated Immune Regulation in order to Treat Cancer

TITLE: INHIBITION OF YAP FOR BREAKING TUMOR IMMUNE TOLERANCECASE NUMBER: C13353UNMET NEEDRegulatory T cells (Tregs) play critical roles in maintaining self-tolerance and homeostasis by suppressing the activation and function of other immune cells. At the same time, the immune-dampening effects of Tregs can inhibit the development...

Published: 9/26/2024 | Inventor(s): Benjamin Park, Drew Pardoll, Duojia Pan, Joseph Barbi, Fan Pan

Keywords(s): Biomarker, Cancers, Disease Indication, Mechanism-of-action Biomarker, Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Cancer Therapy via a Combination of Epigenetic Modulation and Immune Modulation

In addition to the conventional forms of cancer therapy (chemotherapy, surgery, radiation), newer forms of therapy, including epigenetic modulation with DNA demethylating agents and HDAC inhibitors and therapies targeted at the immune system, are being investigated. We have discovered that epigenetic modulation alters tumor gene expression so as to...

Published: 9/26/2024 | Inventor(s): Suzanne Topalian, Stephen Baylin, Drew Pardoll

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Biomarker, Cancers, Clinical Diagnostics, Combination, Disease Indication, Epigenetic, In Vitro Diagnostics, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

1 2